CAM
GLUE icon

Cormorant Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Cormorant Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-400,000
Closed -$6.58M – 54
2026
Q1 		$6.58M Buy
+400,000
New +$7.65M 0.33% 42
2023
Q2 		– Sell
-2,893,717
Closed -$22.5M – 71
2023
Q1 		$22.5M Hold
2,893,717
– – 1.48% 18
2022
Q4 		$22M Sell
2,893,717
-100,000
-3% -$833K 1.47% 23
2022
Q3 		$24.5M Hold
2,993,717
– – 1.71% 21
2022
Q2 		$28.9M Sell
2,993,717
-8,482
-0.3% -$85.2K 2.19% 14
2022
Q1 		$42.1M Hold
3,002,199
– – 3.23% 9
2021
Q4 		$61.3M Sell
3,002,199
-100,000
-3% -$2.09M 3.65% 6
2021
Q3 		$68M Sell
3,102,199
-91,774
-3% -$2.63M 2.76% 10
2021
Q2 		$69.5M Buy
+3,193,973
New +$65.1M 2.36% 10

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cormorant Asset Management's GLUE Position: Q2 2026 in Review

Cormorant Asset Management sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 400,000 shares — an estimated $6.58M sold.

Cormorant Asset Management first reported a position in GLUE in Q2 2021 and held it in 9 quarters. The position peaked at $69.5M in Q2 2021. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Cormorant Asset Management reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cormorant Asset Management sold 400,000 Monte Rosa Therapeutics shares in Q2 2026, an estimated $6.58M.
  • Cormorant Asset Management first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 9 quarters.
  • Cormorant Asset Management's Monte Rosa Therapeutics position peaked at $69.5M in Q2 2021.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.